Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
The Food and Drug Administration (FDA) has granted expanded approval of the radioligand therapy 177Lu-PSMA-617 (Pluvicto®, Novartis) for patients with metastatic castration-resistant prostate cancer (mCRPC).
For patients with prostate-specific membrane antigen (PSMA) positive mCRPC, Pluvicto may be utilized for those who have received an androgen receptor pathway inhibitor (ARPI) and prior to the use of chemotherapy, according to Novartis.
For patients with prostate-specific membrane antigen (PSMA) positive mCRPC, the FDA has granted expanded approval of the radioligand therapy Pluvicto for those who have received an androgen receptor pathway inhibitor (ARPI) and prior to the use of chemotherapy. (Image courtesy of Adobe Stock.)
A recently published phase 3 trial revealed that Pluvicto, in comparison to a change of ARPI, reduced the risk of radiographic progression and death by 59 percent in this patient population.
Novartis added that the primary adverse events for patients treated with Pluvicto in the study were dry mouth (61 percent), fatigue (53 percent) and nausea (32 percent).
"This approval is a significant step forward and should open the doorway to a therapy that has clear clinical advantages for the patient with mCRPC who has progressed on one ARPI and has not received chemotherapy,” emphasized Michael Morris, M.D., the principal investigator of the study and prostate cancer section head at the Memorial Sloan Kettering Cancer Center in New York City.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
